newswire, breaking biotechnology and pharma news

Sunday, October 17, 2010

Biotech Stocks to Watch for Monday; (OTCBB: UVFT), (AMEX: PIP), (NASDAQ:VVUS), (NASDAQ: AMGN)

Biotech Stocks to Watch for Monday; (OTCBB: UVFT), (AMEX: PIP), (NASDAQ:VVUS), (NASDAQ: AMGN)

Point Roberts, WA –October 17, 2010 ( Newswire, -, a leader in sector research for investors, reports on recent Biotech/ Pharma Stocks news and trading. Biotech Stocks to follow for Monday morning include UV Flu Technologies, Inc., (OTCBB: UVFT), PharmAthene, Inc. (AMEX: PIP), VIVUS Inc (NASDAQ:VVUS), and Amgen Inc., (NASDAQ: AMGN).

Biotech Sector Snapshot: (Trading at Market close Friday October 15)

UV Flu Technologies, Inc., (OTCBB: UVFT) trading at $ 0.27

PharmAthene, Inc. (AMEX: PIP), trading at $ 3.19, up 1.21 (61.11%) on Volume of 22,685 ,355 shares

VIVUS Inc (NASDAQ:VVUS), trading at $6.53, (0.76 %)

Amgen Inc., (NASDAQ: AMGN) trading at $ 56.71, up 1.85 (3.37%)

Biotech Stocks to Watch; Recent News

UV Flu Technologies, Inc., (OTCBB: UVFT) Key Highlights and Recent Press

UV Flu Technologies, Inc., (OTCBB: UVFT) is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the VIRATECH UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. UV Flu is committed to providing clean air to improve health and prevent the spread of disease.

UV Flu Technologies Inc., already has FDA Approval as a Class II Medical Device making the company ahead of its competitors and a Biotech Stock to watch

Latest News:

UV Flu Technologies Announces Development of Residential Market Bacteria Killing Indoor Air Purifier to Be Based on Laboratory Proven Design

“UV Flu Technologies, Inc. is pleased to announce that in response to interest from the marketplace, the company intends to rapidly roll out the development of a residential sector air purifier offering features specifically designed for the residential marketplace. The new unit will be designated UV-200 and will be designed with the needs of the health-conscious homeowner in mind.

"Our current UV-400 air purifier sets a very high standard, and is unique in the marketplace, but was primarily conceived for the demands of the commercial marketplace," said Jack Lennon, President of UV Flu Technologies. "Our UV-400 kills airborne bacteria in larger spaces up to 700-900 sq. feet, whereas typical HEPA filter units generally cover a space from 100-200 sq. feet. Our unit keeps on killing contaminants long after the filter units have lost their efficacy as they are not dependent on changing, or washing filters continuously."

Full Article:


UV Flu Technologies, Inc., Key Highlights

• FDA Approved as a Class II Medical device

• Extensive testing by EPA and FDA certified laboratories

confirm the proprietary system has over 99% effectiveness of eliminating bacteria

• The Company’s strategic differentiators include excellent independent test

results proving the effectiveness and safety of its products, proprietary design,

and FDA market clearance approving the sale of its products as medical


• The Company has been issued U.S. Patent No. 6939397 with 43 claims covering

its innovative removable cartridge, housing, UV chamber, UV radiation

source and baffle technology.

• UV Flu’s products are environmentally friendly. The energy efficient system

does not use or produce ozone, uses less energy than a 100 watt light bulb

and can qualify for Green Building programs.

• Experts have warned that a new type of drug-resistant superbug is emerging.

NDM-1 is a gene carried by bacteria that makes the strain resistant to some of

the most powerful antibiotics. NDM-1 can easily now jump from one strain of

bacteria to another.

PharmAthene, Inc. (AMEX: PIP)

PharmAthene, Inc. (AMEX: PIP) Recent News: “PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today that based on information provided by PharmAthene in its compliance plan, and discussions with Exchange staff, the NYSE Amex LLC has determined that the Company made a reasonable demonstration of its ability to regain compliance with the NYSE Amex listing requirements and granted PharmAthene an extension until January 26, 2012 to demonstrate its compliance. ”

Full Article:

About PharmAthene, Inc. (AMEX: PIP): PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

SparVax(TM) -- a second generation recombinant protective antigen (rPA) anthrax vaccine

Third generation rPA anthrax vaccine

Valortim(R)-- a fully human monoclonal antibody for the prevention and treatment of anthrax infection

Protexia(R) -- a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents

For more information about PharmAthene, please visit .

About is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. is known for its comprehensive stock directories in each sector and sector specific newswires.

Research more biotech stocks at the Biotech stocks Directory:

About our Biotech investor portal: is a global meeting place for investors and industry following the biotech/pharma sector, within Global visitors use the site daily to research the latest news, articles, audio, research reports and our global stock directories.

Disclaimer: The following news is paid for by a third party on behalf of UV Flu Technologies, Inc., (three thousand per month) as a showcase stock. is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclaimer: Disclosure:

C Van Zant: 800-665-0411 -

Source -

No comments:

Post a Comment